Sangamo Therapeutics Aktie [WKN: 936386 / ISIN: US8006771062]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Sangamo Therapeutics Inc

19.11.24		Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain (Businesswire)
12.11.24		Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results (Businesswire)
04.11.24		Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast (Businesswire)
22.10.24		Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 (Businesswire)
06.08.24		Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results (Businesswire)
06.08.24		Sangamo Signs Licensing Deal With Genentech To Develop Intravenous Genomic Medicines; Stock Up (RTTNews)
06.08.24		Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases (Businesswire)
30.07.24		Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast (Businesswire)
24.07.24		Sangamo Soars On Pfizer's Hemophilia A Gene Therapy Trial Results (RTTNews)
24.07.24		Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate (Businesswire)
09.05.24		Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results (Businesswire)
09.05.24		Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing (Businesswire)
02.05.24		Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast (Businesswire)
22.03.24		Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering (Businesswire)
13.03.24		Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results (Businesswire)
13.03.24		Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs (Businesswire)
12.03.24		Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast (Businesswire)
12.02.24		Sangamo Therapeutics Reports U.S. And European Regulatory Support For ST-920 (RTTNews)
12.02.24		Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease (Businesswire)
06.02.24		Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile (Businesswire)
01.11.23		Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results (Businesswire)
25.10.23		Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast (Businesswire)
20.09.23		Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit (Businesswire)
08.08.23		Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results (Businesswire)
01.08.23		Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast (Businesswire)
20.07.23		Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing (Businesswire)
17.07.23		Sangamo Inks Evaluation And Option Agreement With Lilly's Prevail For Adeno-associated Virus Capsids (RTTNews)
17.07.23		Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids (Businesswire)
29.06.23		Sangamo Gets License To Combine Voyager TRACER Capsid With Sangamo's ZF-TRs To Treat Prion Disease (RTTNews)
29.06.23		Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease (Businesswire)
22.05.23		Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease (Businesswire)
16.05.23		Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer (Businesswire)
02.05.23		Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (Businesswire)
26.04.23		Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results (Businesswire)
19.04.23		Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast (Businesswire)
22.02.23		Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results (Businesswire)
22.02.23		Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease (Businesswire)
21.02.23		Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast (Businesswire)
03.11.22		Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results (Businesswire)
27.10.22		Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast (Businesswire)
12.10.22		Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Nine Patients (Businesswire)
04.08.22		Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results (Businesswire)
28.07.22		Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast (Businesswire)
21.07.22		European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation (Businesswire)
01.06.22		Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences (Businesswire)
05.05.22		Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results (Businesswire)
02.05.22		Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (Businesswire)
28.04.22		Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast (Businesswire)
21.04.22		Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences (Businesswire)
29.03.22		Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation (Businesswire)

1 | Weiter

Newssuche

Sangamo Therapeutics Peer Group Nachrichten

17.12.24		NASDAQ-Handel NASDAQ Composite verliert schlussendlich
16.12.24		Optimismus in New York: Letztendlich Pluszeichen im NASDAQ Composite
16.12.24		NASDAQ Composite aktuell: So entwickelt sich der NASDAQ Composite am Montagnachmittag
16.12.24		Pluszeichen in New York: Anleger lassen NASDAQ Composite am Mittag steigen
16.12.24		Handel in New York: Zum Start Gewinne im NASDAQ Composite
13.12.24		Optimismus in New York: NASDAQ Composite letztendlich mit Zuschlägen
13.12.24		NASDAQ-Handel NASDAQ Composite am Nachmittag mit Abgaben
13.12.24		Börse New York in Rot: So entwickelt sich der NASDAQ Composite mittags

Meistgelesene Nachrichten

Mit Ripple Millionär werden? So klappt’s!

Pierer Mobility-Aktie verliert: Insolvente KTM zahlt Dezember-Gelder doch nicht vorzeitig und stoppt Produktion

Israels Armee: Hamas-Kommandozentrale in Gaza angegriffen

Bitcoin klettert über 107.000 US-Dollar und schafft neues Allzeithoch

Analyst sieht Gründe für noch mehr Optimismus: Bitcoin und Aktienmarkt werden weiter steigen

EZB-Zinsentscheid im Blick: ATX schließt mit Gewinnen -- DAX beendet Handel fester -- US-Märkte letztendlich schwach -- Börsen in Japan und China schließen mit Zuwächsen

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	18.12.2024 05:27
Kaufwert:	EUR
	Hinzufügen Speichern